WO1992006699A1 - Plant extracts as mucosal-protective agents - Google Patents

Plant extracts as mucosal-protective agents Download PDF

Info

Publication number
WO1992006699A1
WO1992006699A1 PCT/US1991/007014 US9107014W WO9206699A1 WO 1992006699 A1 WO1992006699 A1 WO 1992006699A1 US 9107014 W US9107014 W US 9107014W WO 9206699 A1 WO9206699 A1 WO 9206699A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant
extract
tissues
alcohol
butanol
Prior art date
Application number
PCT/US1991/007014
Other languages
French (fr)
Inventor
Tuticorin Govindachari Rajagopalan
Jared Lynn Randall
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of WO1992006699A1 publication Critical patent/WO1992006699A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • C11D1/38—Cationic compounds
    • C11D1/52—Carboxylic amides, alkylolamides or imides or their condensation products with alkylene oxides
    • C11D1/525—Carboxylic amides (R1-CO-NR2R3), where R1, R2 or R3 contain two or more hydroxy groups per alkyl group, e.g. R3 being a reducing sugar rest
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/20—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton

Definitions

  • the subject invention relates to extracts of tissues of certain plant species from the genera Wedelia, Eclipta and Aspilia which are effective as gastrointestinal mucosal- protective agents.
  • Extracts from these plants have also been used to treat a number of other ailments such as catarrh, skin diseases, elephantiasis, toothaches and headaches, as well as being used as emetic and purgative materials, and as external antiseptics.
  • Extracts from these plants have been shown to have antibiotic activity against certain species.
  • the following references disclose activities of extracts of W. calendulacea and E.
  • Antihepatotoxic activity has also been reported for an extract from the plant Wedelia chinensis: Yang, L.-L., K.-Y. Yen, C. Konno, Y. Oshima, Y. Kiso & H. Hikino, "Antihepatotoxic Drugs. Part 32. Antihepatotoxic Principles of Wedelia chinensis Herbs", Planta Medica (1986), No. 6, pp. 499-500. Antibacterial activity has also been discovered in extracts from other plants of the genera Wedelia, Eclipta and Aspilia: Roque, N.F., T.L. Giannella, A.M. Giesbrecht & R.
  • It is another object of the subject invention to provide novel methods for treating or preventing gastrointestinal maladies such as gastritis, non-ulcer dyspepsia, gastroesophageal reflux disease, esophagitis, gastric ulcers, duodenal ulcers, gastric cancer, Zollinger-Ellison syndrome, ethanol-induced damage, non-steroidal anti-inflammatory drug (NSAID)-induced damage, ileitis, Crohn's disease, colitis, ulcerative colitis, and inflammatory bowel disease.
  • gastrointestinal maladies such as gastritis, non-ulcer dyspepsia, gastroesophageal reflux disease, esophagitis, gastric ulcers, duodenal ulcers, gastric cancer, Zollinger-Ellison syndrome, ethanol-induced damage, non-steroidal anti-inflammatory drug (NSAID)-induced damage, ileitis, Crohn's disease, colitis, ulcerative colitis, and inflammatory bowel disease.
  • NSAID non-steroidal anti-
  • the subject invention relates to methods for providing mucosal protection in the gastrointestinal tract comprising administering to a human or lower animal a safe and effective amount of an extract from certain plant species of the genera Wedelia, Eclipta and Aspilia.
  • the subject invention involves extracts from the tissues of certain plant species which provide mucosal-protective activity against gastrointestinal disorders of the upper and lower gastrointestinal tract.
  • upper gastrointestinal refers to the esophagus, the stomach and the duodenum.
  • lower gastrointestinal refers to the jejunum, the ileum and the colon.
  • mucosal-protective means mucosal-protective in the gastrointestinal tract.
  • compositions comprising the extracts of the subject invention include gastritis, non-ulcer dyspepsia, gastroesophageal reflux disease, esophagitis, gastric ulcers, duodenal ulcers, gastric cancer, Zollinger-Ellison syndrome, ethanol -induced damage and NSAID- induced damage.
  • the compositions of the subject invention are particularly useful for treatment of gastritis, gastric ulcers, duodenal ulcers, non-ulcer dyspepsia, ethanol-induced damage and NSAID-induced damage, especially gastritis, non-ulcer dyspepsia and NSAID-induced damage.
  • the compositions of the present invention are particularly useful for prophylactic protection from gastric ulcers, ethanol-induced damage and NSAID-induced damage, especially NSAID-induced damage.
  • the compositions of the subject invention are particularly useful for treatment of regional and erosive stages of ileitis, colitis and inflammatory bowel disease, especially inflammatory bowel disease.
  • Extracts of the subject invention which are useful for the treatment of gastrointestinal disorders of the upper gastrointestinal tract are obtained from species of the genera Wedelia, Eclipta and Aspilia; preferred species from which such extracts are obtained include A. floribunda, A. parvifloia, E. alba, E. erecta, E. prostrata, W. asperrima, W. biflora, W. buphthalmiflora, W. calendulacea, W. calycina, W. chinesis, W. forsteriana, W. glauca, W. grandiflora, W. helianthoides, W. hispida, W. hookeriana, W. keatingii. W. paludosa, W. parviceps, W. pine- torum, W. scaberrima and W. trilobata. Particularly preferred are extracts from E. alba and especially W. calendulacea.
  • Extracts from the above plant species which are included in the subject invention are those which have mucosal-protective activity. It has been found that a wide variety of extraction solvents can be used to obtain extracts of these plant species having mucosal-protective activity. As used herein, "mucosal- protective activity" of an extract or composition can be determined using the following procedure.
  • Rats Male male rats (CD strain) weighing 185 to 195 grams each are purchased from Charles River Breeding Laboratories (Portage, MI). Upon receipt, rats are double-housed in stainless steel mesh-bottom cages with access to automatic water and Purina rat chow in. the form of pellets. The animal room is maintained at 20-23oC and 50-60% relative humidity with a twelve hour light/dark cycle. Animals are allowed to acclimate for 7 days prior to use.
  • Dose Solution Preparation Appropriate weights of extract and distilled deionized water are shaken or stirred magnetically. When necessary, the pH of the solution is adjusted with either sodium hydroxide or hydrochloric acid to near neutrality (pH 5 to 7.5). Solutions are stirred magnetically while dosing.
  • Extracts of the subject invention may be obtained from a variety of tissues from the above-identified plant species. Extracts from the above-ground tissues of the plants are preferred, especially from the leaves. Extracts may be made from fresh plant tissues, or from the tissues after they are dried. Preferred are extracts of dried leaves.
  • extracting or “extraction” of a solid or liquid material means contacting the material, which if solid is preferably dried and crushed or ground, with an appropriate solvent to remove the substance(s) desired to be extracted from the material.
  • an extraction may be carried out by conventional means; for example, by using an extraction apparatus, such as a Soxhlet apparatus, which retains the solid material in a holder and allows the solvent to flow through the material; or by blending the solvent and material together and then separating the liquid and solid phases or two immiscible liquid phases, such as by filtration or by settling and decanting.
  • Preferred extracts of the subject invention are made from defatted plant tissues, especially defatted dried leaves.
  • Defatted plant tissues can be prepared by extracting the plant tissues using an appropriate solvent.
  • Preferred solvents include methylene chloride, hexane, pentane, petroleum ether, chloroform and ethylene dichloride, especially methylene chloride.
  • 1 part of plant tissue (dry basis) is extracted with from about 5 to about 50 parts, preferably from about 15 parts to about 30 parts of solvent using an extraction apparatus where the solvent is refluxed through the tissues for a long period of time, preferably from about 6 hours to about 7 days, more preferably for about 1-4 days.
  • the defatted plant tissues are preferably dried prior to further extraction steps.
  • the subject invention includes a process for preparing a weak acid extract of tissues of the plants of interest, preferably of leaves, especially dried leaves, by extracting the tissues with an aqueous acid solution having a pH of from about 1.5 to about 5, preferably from about 2 to about 4, more preferably from about 2.5 to about 3.5.
  • Preferred weak acids include malic, formic, lactic, tartaric, acetic and citric, and also include dilute strong acids such as sulfuric and hydrochloric.
  • Preferred is acetic acid.
  • natural juices which are weak acids, such as citric juices, especially lemon juice.
  • 1 part of plant tissues (dry basis) is extracted using from about 5 to about 20 parts, preferably from about 8 to about 10 parts of aqueous acid solution, the solution preferably being from about 1% to about 5%, more preferably about 2%, acid.
  • a mixture of the tissues and acetic acid solution is preferably stirred for from about 2 to about 24 hours, preferably for from about 3 to about 5 hours.
  • the resulting liquid extract is separated from the plant tissue residue.
  • the liquid extract is preferably dried by conventional means such as by rotary evaporation, freeze drying or spray drying, to provide a solid weak acid extract.
  • the subject invention includes a process for preparing a weak acid extract of tissues of the plants of interest, by extracting the tissues with lemon juice.
  • the tissues of plants preferably extracted are the leaves; especially preferred is extracts of dried leaves.
  • 1 part of plant tissues (dry basis) is extracted using from about 1 to about 10 parts, preferably from about 2 to about 3 parts of lemon juice, preferably freshly squeezed, and preferably with from about 5 to about 20 parts, more preferably from about 8 to about 10 parts of water.
  • the mixture is preferably stirred for from about 2 to about 24 hours, more preferably for from about 3 to about 5 hours.
  • the resulting liquid extract is separated from the plant tissue residue.
  • the liquid extract is preferably dried by conventional means, such as by evaporation, freeze drying or spray drying to provide a solid lemon juice extract.
  • the subject invention includes a process for preparing an alcohol extract of tissues of the plants of interest, preferably of leaves, especially dried leaves, by extracting the tissues using water-miscible alcohol, such as methanol, ethanol, n-propanol or ispropanol or mixtures of such alcohols with up to about 50% water; the preferred alcohol is methanol.
  • water-miscible alcohol such as methanol, ethanol, n-propanol or ispropanol or mixtures of such alcohols with up to about 50% water; the preferred alcohol is methanol.
  • 1 part of plant tissues (dry basis) is extracted with from about 5 to about 50 parts, more preferably from about 15 to about 30 parts of solvent, using an extraction apparatus, where the solvent is refluxed thru the tissues, for a period of from about 4 to about 48 hours, preferably for from about 12 to about 24 hours.
  • the alcohol is preferably evaporated from the resulting liquid alcohol extract, that providing a solid alcohol extract.
  • the alcohol extract may optionally be acid treated by dissolving it in acid and separating out any solid residue.
  • the alcohol extract is mixed with an acid solution, preferably a weak acid solution such as 0.1 N HCl.
  • a weak acid solution such as 0.1 N HCl.
  • 1 part of solid alcohol extract is mixed with from about 10 to about 1000 parts, more preferably about 100 parts of acid solution. Residual solids are separated from the solution, preferably by filtration.
  • the filtrate is neutralized, preferably with a weak base such as 0.1 N NaOH. Water is preferably evaporated from the resulting solution to provide solid acid-treated alcohol extract.
  • the subject invention includes a process for preparing a
  • the resulting liquid 1-butanol extract is separated from the remaining water phase, and preferably the 1-butanol is evaporated from the liquid 1-butanol extract to provide a solid 1-butanol extract.
  • 1 part of alcohol extract (dry basis) is dissolved in from about 30 to about 300 parts, more preferably from about 100 to about 150 parts of water.
  • the resulting aqueous solution is preferably mixed with from about 0.1 to about 2 parts, more preferably about 0.5 parts of 1-butanol.
  • the 1-butanol extraction is carried out in from about 1 to about 4 steps, more preferably about 2 steps, by dividing the quantity of 1-butanol into about equal portions and separately mixing each portion of 1-butanol with the alcohol extract solution and then separating the 1-butanol phase from the aqueous phase.
  • the 1-butanol portions are combined to provide a liquid 1-butanol extract, and preferably the 1-butanol is evaporated to provide a solid 1-butanol extract.
  • water is preferably added, followed by further evaporation to remove the residual 1-butanol.
  • the aqueous solution is then preferably dried to obtain the solid 1-butanol extract.
  • Freeze drying is a preferred method for drying aqueous solutions in the above processes.
  • Dried leaves are obtained from one or more desired Wedelia, Eclipta and/or Aspilia species.
  • the dried leaves are crushed with a mortar and pestle, or with a ball-mill apparatus.
  • the powdered material obtained is passed through a 60-mesh screen.
  • the 60-mesh powder obtained is used in the extraction procedures.
  • Acetic Acid Extract Powdered leaves (100 g) from Example 1, acetic acid (18 mL), and distilled water (900 mL) (provides a 2% aqueous acetic acid solution) are added to a 2-L round-bottom flask. The mixture obtained is stirred with a mechanical stirrer for 4 hours. Filtration of the dark green mixture through muslin cloth provides a turbid, dark green solution. The solution is freeze-dried to provide a dark green acetic acid extract solid (17.1 g).
  • Methanol Extract Powdered leaves (50 g) from Example 1 are placed in an extraction thimble which is then placed in a Soxhiet extraction apparatus. Methanol (1.5 L) is added to the distillation pot of the Soxhiet apparatus and the solvent is refluxed through the extraction thimble for 12 hours. The methanol solution is evaporated on a rotary evaporator, and the dark gummy residue obtained is dried in vacuo. The dark green solid obtained is crushed to provide a methanol extract powder (3.7 g).
  • Powdered leaves (133 g) from Example 1 are placed in an extraction thimble which is then placed in a Soxhiet apparatus.
  • Methylene chloride (1 L) is placed in the distillation pot of the apparatus and the leaf material is continuously extracted for 4 days.
  • the leaf residue is removed from the extraction apparatus and dried in air and then in vacuo.
  • the dried leaf material (115 g) is placed in an extraction thimble which is then placed in a Soxhiet extraction apparatus.
  • Methanol (1.5 L) is added to the distillation pot of the Soxhiet apparatus and the solvent is refluxed through the extraction thimble for 4 days.
  • the methanol solution is evaporated on a rotary evaporator, and the dark residue obtained is dried in vacuo.
  • the dark green solid obtained is crushed to provide defatted methanol extract powder (14.3 g).
  • This extract is then added to 0.1N HCl aqueous solution (600 mL) and magnetically stirred (20 minutes).
  • the solution is placed into vessels which are centrifuged at 5 G. After 10 minutes, the supernatant is removed and the pH is adjusted to 7.8 by the addition of 0.1 N NaOH solution.
  • the aqueous solution is then extracted once with 1-butanol (300 mL).
  • the 1-butanol solution obtained is combined with water (250 ml) and evaporated on a rotary evaporator.
  • n-propanol is largely evaporated on a rotary evaporator and the remaining aqueous solution is extracted with 1 x 200 mL and further 2 x 100 mL hexane for defatting.
  • the aqueous fraction is further extracted with 4 x 100 mL water-saturated 1-butanol.
  • the 1-butanol is evaporated on a rotary evaporator and the dark, gummy residue is dried in vacuo. The dark green solid obtained is crushed to provide a defatted 1-butanol extract (10 g).
  • compositions comprising an extract of the subject invention, such as described hereinabove, and a pharmaceutically-acceptable carrier.
  • Preferred compositions are those in dosage forms intended for oral administration.
  • Fluid dosage forms for oral administration include solutions, suspensions, emulsions, and the like.
  • Solid dosage forms for oral administration include tablets, capsules, powders, lozenges, and the like.
  • pharmaceutically-acceptable carrier means one or more compatible solid or liquid filler diluent or encapsulating substance which is suitable for administration to a human or lower animal.
  • compatible means that the components of the pharmaceutical carrier are capable of being commingled with the extracts of the subject invention, in a manner such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the composition under ordinary use situations.
  • Pharmaceutically-acceptable carriers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the human or lower animal being treated.
  • substances which can serve as pharmaceutically-acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch, cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate; powdered tragacanth; malts; gelatin; talc; steric acid; magnesium stearate; calcium sulfate; vegetable oil such peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; purified water; emulsifiers, such as the Tweens ® ; as well as other non-toxic compatible substances used in the pharmaceutical formulation.
  • Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, excipients, tableting agents,
  • compositions of the subject invention are not intended to be limiting with regard to useful compositions that can be prepared from the extracts of the subject invention.
  • Capsules The spray-dried powder lemon juice extract of Example 2 is used to prepare capsules by blending 2 parts of the extract with 1 part sucrose and granulating by adding ethanol and blending. The wet granules are dried and passed through a 22-mesh screen; fines are removed with a 30-mesh screen. Hard gelatin capsule shells are filled with 550 mg of granules in each capsule using conventional means.
  • Coated Granules The dried, powdered acetic acid extract of Example 4 is granulated by blending 6 parts of the powdered extract with 13 parts sucrose and 1 part sodium chloride. These materials are passed through a 40-mesh screen and ethanol is added as the granulating agent. The granules are passed through a 22-mesh screen and dried. Fines are removed with a 30-mesh screen. The granules are transferred to a coating pan and coated initially with 18 parts of a 5% hydroxypropylmethyl cellulose solution (the solvent being a 2:1 mixture of dichloromethane: ethanol) with intermittent addition of 0.14 part of peppermint oil flavor.
  • the granules are then coated with 14 parts of a 2.5% hydroxypropylmethyl cellulose solution followed by drying.
  • the granules are passed through a 16-mesh screen and fines are removed with a 30-mesh screen. The retained granules are packed into sachets.
  • Tablets The dried, powdered 1-butanol extract of Example 9 is granulated by blending 6 parts with 13 parts sucrose and 1 part sodium chloride, and using ethanol as the granulating liquid. The granules are passed through a 16-mesh screen and dried; fines are removed with a 44-mesh screen. 100 Parts granules are blended with 2 parts talc and 1 part magnesium stearate. This mixture is compressed into 1-gram tablets by conventional means.
  • Another aspect of the subject invention includes methods for treating or preventing gastrointestinal disorders in humans or lower animals by administering, to a human or lower animal in need of such treatment or prevention, a safe and effective amount of an extract or a composition of the subject invention.
  • This safe and effective amount can be given in a single dose or multiple doses repeatedly over the course of the treatment.
  • Preferred methods of administering the compositions of the subject invention include peroral, intraperitoneal, or directly (e.g., by tube) to the afflicted part of the gastrointestinal tract, especially peroral.
  • safe and effective amount means an amount of the composition of the subject invention high enough to significantly modify the condition to be treated in a positive way, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgement.
  • the safe and effective amount of a composition will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of treatment, the nature of concurrent therapy, the specific composition employed, the particular pharmaceutically-acceptable carrier utilized, and like factors within the knowledge and expertise of the attending physician.
  • the methods of the subject invention include treatment of humans and lower animals, especially humans, currently suffering from one or more upper or lower gastrointestinal disorders, particularly those specified hereinbefore, in order to reduce the severity of the disorder.
  • the methods of the subject invention also include the prevention of upper or lower gastrointestinal disorders in humans and lower animals, especially humans, having a propensity for such disorders, particularly those specified hereinbefore, by prophylactic treatment in order to prevent occurrence of the disorder.
  • the methods of the subject invention include administering to a human or lower animal a composition comprising an extract of the subject invention.
  • the quantity of extract (dry basis) administered is preferably from about 1 mg/kg to about 1000 mg/kg of body weight, more preferably from about 5 mg/kg to about 500 mg/kg, more preferably still from about 10 mg/kg to about 200 mg/kg. These quantities of extract are preferably administered from about 1 to about 4 times daily, more preferably 2 or 3, or especially about 4 times daily.
  • the extract is preferably administered from about 0 to about 2 hours before meals, more preferably from about 1/2 hour to about 1 hour before meals.
  • the extracts of the subject invention have a rapid onset of action, and are particularly suitable for treatment of occasional gastrointestinal disorders, such as gastritis, non-ulcer dyspepsia and gastroesophageal reflux disease, as needed.
  • Such disorders are preferably treated using a composition, such that the extract of the subject invention is dosed at a level of from about 1 mg/kg to about 1000 mg/kg, more preferably from about 5 mg/kg to about 500 mg/kg, more preferably still from about 10 mg/kg to about 200 mg/kg, as needed at the onset or during symptomatic episodes of such disorders.
  • additional doses are preferably administered at intervals of from about 1 to about 6 hours, more preferably at intervals of about 2 or 3 or 4 hours.
  • compositions of the subject invention be administered from 0 to about 6 hours, more preferably from about 1/4 hour to about 3 hours, more preferably still from about 1/2 hour to about 1 hour, prior to administration of the NSAID.
  • preferred doses of extracts of the subject invention are from about 1 mg/kg to about 1000 mg/kg, more preferably from about 5 mg/kg to about 500 mg/kg, more preferably still from about 10 mg/kg to about 200 mg/kg.
  • a person afflicted with colitis ingests 1 capsule of Example 11 every 8 hours for 7 days to obtain relief from the symptoms of the disease.
  • a person afflicted with gastritis ingests 1 gram of the granulus of Example 12 to obtain rapid relief from the gastritis symptoms.
  • a person determined to be at high risk of developing a gastric ulcer ingests 1 of the tablets of Example 13 daily for 6 months to prevent the occurrence of an ulcer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Fats And Perfumes (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The subject invention relates to methods for providing mucosal-protection comprising administering to a human or lower animal a safe and effective amount of an extract from plant species of the genera Wedelia, Eclipta and Aspilia.

Description

PLANT EXTRACTS AS MUCOSAL-PROTECTIVE AGENTS
TECHNICAL FIELD
The subject invention relates to extracts of tissues of certain plant species from the genera Wedelia, Eclipta and Aspilia which are effective as gastrointestinal mucosal- protective agents.
BACKGROUND OF THE INVENTION
Various species from the genera Wedelia, Eclipta and Aspilia have been disclosed to have a variety of different biological or pharmacological activities.
Two frequently studied species of these genera are Wedelia caiendulaceae and Eclipta alba. The most common medicinal use of extracts from these plants is for treatment of liver ailments. For this use, the active compounds found in these species are believed to be coumestans, especially wedelolactone and related compounds. Extracts from these plants have also been used to treat a number of other ailments such as catarrh, skin diseases, elephantiasis, toothaches and headaches, as well as being used as emetic and purgative materials, and as external antiseptics. Shoot extracts have been shown to have antibiotic activity against certain species. The following references disclose activities of extracts of W. calendulacea and E. alba, methods for obtaining extracts from them, and active components isolated from the extracts: Bhargava, K.K & T.R. Seshadri, "Chemistry of Medicinal Plants: Eelipta alba and Wedelia calendulacea", Journal of Research of Indian Medicine, Vol. 9, No. 1 (1974), pp. 9-15; Wagner, H., B. Geyer, Y. Kiso, H. Hikino & G.S. Rao, "Coumestans as the Main Active Principles of the Liver Drugs Eclipta alba and Wedelia calendulacea", Planta Medica, Vol. 5 (1986), pp. 370-374; Handa, S.S., P. Prakash & B. Roy, "Bioactivity Directed Extraction and Fractionation of Eclipta alba - an Antihepatotoxic Drug of Indian Origin", Indian Journal of Pharmaceutical Sciences, (Jan.-Feb., 1984), p. 50 (abstract only); Govindachari, T.R., K. Nagarajan & B.R. Pai, "Chemical Examination of Wedelia calendulacea. Part I. Structure of Wedelolactone", Journal of the Chemical Society, (1956), pp. 629-632; Govindachari, T.R., K. Nagarajan, B.R. Pai & P.C. Parthasarathy, "Chemical Investigation of Wedelia calendulacea. Part II. The Position of the Methoxyl Group in Wedelolactone", Journal of the Chemical Society, (1957), pp. 545-547; Govindachari, T.R., K. Nagarajan & P.C. Parthasarathy, "Chemical Examination of Wedelia calendulacea. Part III. Synthesis of Tri-O-methylwedelolactone", Journal of the Chemical Society, (1957), pp. 548-551; Govindachari, T.R., K. Nagarajan & P.C. Parthasarathy, "Chemical Examination of Wedel ia calendulacea-IV Synthetic Analogues of Wedelolactone", Tetrahedron, Vol. 15 (1961), pp. 129-131; Govindachari, T.R. & M.S. Premila, "The Benzofuran Norwedelic Acid from Wedelia calendulacea", Phytochemistry, Vol. 24, No. 12 (1985), pp. 3068-3069; Bhargava, K.K., N.R. Krishnaswamy, & T.R. Seshadri, "Isolation of Desmethylwedelolactone & Its Glucoside from Eclipta alba", Indian Journal of Chemistry, Vol. 8 (1970), pp. 664-665; Bhargava, K.K, N.R. Krishnaswamy & T.R. Seshadri, "Desmethylwedelolactone Glucoside from Eclipta alba Leaves", Indian Journal of Chemistry, Vol 10 (August, 1972), pp. 810-811; Wagner, H. & B. Fessler, "In-Vitro-5-Lipoxygenasehemmung durch Eclipta alba Extrakte und das Coumestan-Derivat Wedelolacton", Planta Medica, (1986), No. 5, pp. 374-377; Krishnaswamy, N.R., T.R. Seshadri & B.R. Sharma, "The Structure of a New Polythienyl from Eclipta alba", Tetrahedron Letters, No. 35 (1966), pp. 4227-4230; and German Patent Application No. DE3,525,363 of Medice Chem.-pharm. Fabrik Putter GmbH & Co. KG, Inventor H. Wagner, published January 22, 1987.
Antihepatotoxic activity has also been reported for an extract from the plant Wedelia chinensis: Yang, L.-L., K.-Y. Yen, C. Konno, Y. Oshima, Y. Kiso & H. Hikino, "Antihepatotoxic Drugs. Part 32. Antihepatotoxic Principles of Wedelia chinensis Herbs", Planta Medica (1986), No. 6, pp. 499-500. Antibacterial activity has also been discovered in extracts from other plants of the genera Wedelia, Eclipta and Aspilia: Roque, N.F., T.L. Giannella, A.M. Giesbrecht & R. Barbosa, "Kaurene Diterpenes from Wedelia paludosa", Rev. Latinoamer. Quim., Vol 18, No. 3 (1987), pp. 110-111; Farouk, A., A.K. Bashir & A.K.M. Salih, "Antimicrobial Activity of Certain Sudanese Plants used in Folkloric Medicine. Screening for Antibacterial Activity (I)", FTRPAE, Fitoterapia, Vol. 54, Issue 1 (1983), pp. 3-7; Rodriguez, E., M. Aregullin, T. Nishida, S. Uehara, R. Wrangham, Z. Abramowski, A. Finlayson & G.H.N. Towers, "Thiarubrine A, a Bioactive Constituent of Aspilia (Asteraceae) consumed by Wild Chimpanzees", Experientia, Vol. 41 (1985), pp. 419-420; and "Chimpanzees Guide Researchers to New Antibiotic", American Pharmacy, Vol. NS26, No.3 (March, 1986), p. 13.
It is an object of the subject invention to provide novel compositions having mucosal-protective activity.
It is another object of the subject invention to provide novel methods for treating or preventing gastrointestinal maladies such as gastritis, non-ulcer dyspepsia, gastroesophageal reflux disease, esophagitis, gastric ulcers, duodenal ulcers, gastric cancer, Zollinger-Ellison syndrome, ethanol-induced damage, non-steroidal anti-inflammatory drug (NSAID)-induced damage, ileitis, Crohn's disease, colitis, ulcerative colitis, and inflammatory bowel disease.
It is also an object of the subject invention to provide novel processes for obtaining extracts from certain plant species having mucosal-protective activity.
SUMMARY OF THE INVENTION
The subject invention relates to methods for providing mucosal protection in the gastrointestinal tract comprising administering to a human or lower animal a safe and effective amount of an extract from certain plant species of the genera Wedelia, Eclipta and Aspilia.
DETAILED DESCRIPTION OF THE INVENTION
The subject invention involves extracts from the tissues of certain plant species which provide mucosal-protective activity against gastrointestinal disorders of the upper and lower gastrointestinal tract. As used herein, "upper gastrointestinal" refers to the esophagus, the stomach and the duodenum. As used herein, "lower gastrointestinal" refers to the jejunum, the ileum and the colon. As used herein, "mucosal-protective" means mucosal-protective in the gastrointestinal tract. As used herein, upper gastrointestinal disorders which can be treated or prevented by administration of compositions comprising the extracts of the subject invention include gastritis, non-ulcer dyspepsia, gastroesophageal reflux disease, esophagitis, gastric ulcers, duodenal ulcers, gastric cancer, Zollinger-Ellison syndrome, ethanol -induced damage and NSAID- induced damage. The compositions of the subject invention are particularly useful for treatment of gastritis, gastric ulcers, duodenal ulcers, non-ulcer dyspepsia, ethanol-induced damage and NSAID-induced damage, especially gastritis, non-ulcer dyspepsia and NSAID-induced damage. The compositions of the present invention are particularly useful for prophylactic protection from gastric ulcers, ethanol-induced damage and NSAID-induced damage, especially NSAID-induced damage.
As used herein, lower gastrointestinal disorders which can be treated or prevented by administration of compositions comprising the extracts of the subject invention include ileitis, Crohn's disease, colitis, ulcerative colitis, and inflammatory bowel disease. The compositions of the subject invention are particularly useful for treatment of regional and erosive stages of ileitis, colitis and inflammatory bowel disease, especially inflammatory bowel disease.
Extracts of the subject invention which are useful for the treatment of gastrointestinal disorders of the upper gastrointestinal tract are obtained from species of the genera Wedelia, Eclipta and Aspilia; preferred species from which such extracts are obtained include A. floribunda, A. parvifloia, E. alba, E. erecta, E. prostrata, W. asperrima, W. biflora, W. buphthalmiflora, W. calendulacea, W. calycina, W. chinesis, W. forsteriana, W. glauca, W. grandiflora, W. helianthoides, W. hispida, W. hookeriana, W. keatingii. W. paludosa, W. parviceps, W. pine- torum, W. scaberrima and W. trilobata. Particularly preferred are extracts from E. alba and especially W. calendulacea.
Extracts from the above plant species which are included in the subject invention are those which have mucosal-protective activity. It has been found that a wide variety of extraction solvents can be used to obtain extracts of these plant species having mucosal-protective activity. As used herein, "mucosal- protective activity" of an extract or composition can be determined using the following procedure.
Test Method
Animals: Adult male rats (CD strain) weighing 185 to 195 grams each are purchased from Charles River Breeding Laboratories (Portage, MI). Upon receipt, rats are double-housed in stainless steel mesh-bottom cages with access to automatic water and Purina rat chow in. the form of pellets. The animal room is maintained at 20-23ºC and 50-60% relative humidity with a twelve hour light/dark cycle. Animals are allowed to acclimate for 7 days prior to use.
To prevent coprophagy, 18 to 24 hours prior to the experiment, cups are affixed to tails with Eastman 910 glue. At the time of tailcupping, rats are weighed, single housed and food fasted with water ad libitum. Unfasted body weights of rats used in experiments range from 225 to 295 grams. One to two hours prior to experiment, the water line is unhooked from the animal rack and the lines drained.
Dose Solution Preparation: Appropriate weights of extract and distilled deionized water are shaken or stirred magnetically. When necessary, the pH of the solution is adjusted with either sodium hydroxide or hydrochloric acid to near neutrality (pH 5 to 7.5). Solutions are stirred magnetically while dosing.
Assay for Ethanol-Induced Gastric Damage: All solutions (water only for Control Group) are dosed orally into the stomach with a small nethalon catheter (8 French) fitted onto a disposable plastic syringe. Dose volume for treatments and ethanol is 1 mL/rat. Ethanol is dosed orally 60 minutes after treatments and rats are sacrificed by cervical dislocation 60 minutes after ethanol administration. Stomachs are dissected, cut along the greater curvature and placed into scintillation vials containing 8-10 mL of 0.9% saline. Approximately 30 to 90 minutes later, stomachs are placed with the mucosal side facing up on numbered cards and damage is observed under a microscope at low power (10X). A Zeiss Zidas Digitizing Pad is used to measure damage. Total length (mm) of lesions for each rat is automatically tabulated by the digitizer.
Statistics: Group statistics are calculated on a computerized spreadsheet. The mean of the total lesion length (mm) for the rats ("Mean Lesions") is calculated for each treatment group and the control group. Percent protection is determined as follows: 1 - (Treatment Group Mean Lesions/Control Group Mean Lesions) X 100. One-way analysis of variance, followed by LSD test, is used to determine differences between treatments (p < 0.05 = significantly different).
Extracts of the subject invention may be obtained from a variety of tissues from the above-identified plant species. Extracts from the above-ground tissues of the plants are preferred, especially from the leaves. Extracts may be made from fresh plant tissues, or from the tissues after they are dried. Preferred are extracts of dried leaves.
As used herein, "extracting" or "extraction" of a solid or liquid material means contacting the material, which if solid is preferably dried and crushed or ground, with an appropriate solvent to remove the substance(s) desired to be extracted from the material. Such an extraction may be carried out by conventional means; for example, by using an extraction apparatus, such as a Soxhlet apparatus, which retains the solid material in a holder and allows the solvent to flow through the material; or by blending the solvent and material together and then separating the liquid and solid phases or two immiscible liquid phases, such as by filtration or by settling and decanting.
Preferred extracts of the subject invention are made from defatted plant tissues, especially defatted dried leaves. Defatted plant tissues can be prepared by extracting the plant tissues using an appropriate solvent. Preferred solvents include methylene chloride, hexane, pentane, petroleum ether, chloroform and ethylene dichloride, especially methylene chloride. Preferably, 1 part of plant tissue (dry basis) is extracted with from about 5 to about 50 parts, preferably from about 15 parts to about 30 parts of solvent using an extraction apparatus where the solvent is refluxed through the tissues for a long period of time, preferably from about 6 hours to about 7 days, more preferably for about 1-4 days. The defatted plant tissues are preferably dried prior to further extraction steps.
The subject invention includes a process for preparing a weak acid extract of tissues of the plants of interest, preferably of leaves, especially dried leaves, by extracting the tissues with an aqueous acid solution having a pH of from about 1.5 to about 5, preferably from about 2 to about 4, more preferably from about 2.5 to about 3.5. Preferred weak acids include malic, formic, lactic, tartaric, acetic and citric, and also include dilute strong acids such as sulfuric and hydrochloric. Preferred is acetic acid. Also preferred are natural juices which are weak acids, such as citric juices, especially lemon juice. Preferably, 1 part of plant tissues (dry basis) is extracted using from about 5 to about 20 parts, preferably from about 8 to about 10 parts of aqueous acid solution, the solution preferably being from about 1% to about 5%, more preferably about 2%, acid. A mixture of the tissues and acetic acid solution is preferably stirred for from about 2 to about 24 hours, preferably for from about 3 to about 5 hours. The resulting liquid extract is separated from the plant tissue residue. The liquid extract is preferably dried by conventional means such as by rotary evaporation, freeze drying or spray drying, to provide a solid weak acid extract.
The subject invention includes a process for preparing a weak acid extract of tissues of the plants of interest, by extracting the tissues with lemon juice. The tissues of plants preferably extracted are the leaves; especially preferred is extracts of dried leaves. Preferably, 1 part of plant tissues (dry basis) is extracted using from about 1 to about 10 parts, preferably from about 2 to about 3 parts of lemon juice, preferably freshly squeezed, and preferably with from about 5 to about 20 parts, more preferably from about 8 to about 10 parts of water. The mixture is preferably stirred for from about 2 to about 24 hours, more preferably for from about 3 to about 5 hours. The resulting liquid extract is separated from the plant tissue residue. The liquid extract is preferably dried by conventional means, such as by evaporation, freeze drying or spray drying to provide a solid lemon juice extract.
The subject invention includes a process for preparing an alcohol extract of tissues of the plants of interest, preferably of leaves, especially dried leaves, by extracting the tissues using water-miscible alcohol, such as methanol, ethanol, n-propanol or ispropanol or mixtures of such alcohols with up to about 50% water; the preferred alcohol is methanol. Preferably, 1 part of plant tissues (dry basis) is extracted with from about 5 to about 50 parts, more preferably from about 15 to about 30 parts of solvent, using an extraction apparatus, where the solvent is refluxed thru the tissues, for a period of from about 4 to about 48 hours, preferably for from about 12 to about 24 hours. The alcohol is preferably evaporated from the resulting liquid alcohol extract, that providing a solid alcohol extract. The alcohol extract may optionally be acid treated by dissolving it in acid and separating out any solid residue. For example, the alcohol extract is mixed with an acid solution, preferably a weak acid solution such as 0.1 N HCl. Preferably, 1 part of solid alcohol extract is mixed with from about 10 to about 1000 parts, more preferably about 100 parts of acid solution. Residual solids are separated from the solution, preferably by filtration. The filtrate is neutralized, preferably with a weak base such as 0.1 N NaOH. Water is preferably evaporated from the resulting solution to provide solid acid-treated alcohol extract.
The subject invention includes a process for preparing a
1-butanol extract from an alcohol extract (an alcohol/1-butanol extract). This process comprises dissolving the alcohol extract
(optionally defatted and optionally acid treated) in water and extracting with 1-butanol. The resulting liquid 1-butanol extract is separated from the remaining water phase, and preferably the 1-butanol is evaporated from the liquid 1-butanol extract to provide a solid 1-butanol extract. In this process, preferably, 1 part of alcohol extract (dry basis) is dissolved in from about 30 to about 300 parts, more preferably from about 100 to about 150 parts of water. The resulting aqueous solution is preferably mixed with from about 0.1 to about 2 parts, more preferably about 0.5 parts of 1-butanol. Preferably the 1-butanol extraction is carried out in from about 1 to about 4 steps, more preferably about 2 steps, by dividing the quantity of 1-butanol into about equal portions and separately mixing each portion of 1-butanol with the alcohol extract solution and then separating the 1-butanol phase from the aqueous phase. The 1-butanol portions are combined to provide a liquid 1-butanol extract, and preferably the 1-butanol is evaporated to provide a solid 1-butanol extract. During evaporation of the 1-butanol, when most of the 1-butanol is evaporated, water is preferably added, followed by further evaporation to remove the residual 1-butanol. The aqueous solution is then preferably dried to obtain the solid 1-butanol extract.
Freeze drying is a preferred method for drying aqueous solutions in the above processes.
The following are examples of extraction processes used for obtaining extracts of the subject invention. They are not intended to be limiting with regard to extraction procedures that can be used.
Example 1
Preparation of Leaf Powders Used in Extraction Procedures: Dried leaves are obtained from one or more desired Wedelia, Eclipta and/or Aspilia species. The dried leaves are crushed with a mortar and pestle, or with a ball-mill apparatus. The powdered material obtained is passed through a 60-mesh screen. The 60-mesh powder obtained is used in the extraction procedures.
Example 2
Preparation of Lemon Juice Extract: Powdered leaves (100 g) from Example 1, freshly squeezed lemon juice (250 mL), and distilled water (900 mL) are added to a 2-L round-bottom flask. The mixture obtained is stirred with a mechanical stirrer for 4 hours. Filtration of the dark green mixture through muslin cloth provides a turbid, dark green solution. A portion of the solution (450 mL) is spray-dried to provide a tan-green lemon juice extract powder (13.9 g). Another portion (200 mL) is freeze-dried to provide a tan-green lemon juice extract powder (5.85 g). Example 3
Preparation of Acetic Acid Extract: Powdered leaves (100 g) from Example 1, acetic acid (18 mL), and distilled water (900 mL) (provides a 2% aqueous acetic acid solution) are added to a 2-L round-bottom flask. The mixture obtained is stirred with a mechanical stirrer for 4 hours. Filtration of the dark green mixture through muslin cloth provides a turbid, dark green solution. The solution is freeze-dried to provide a dark green acetic acid extract solid (17.1 g).
Example 4
Preparation of Defatted Acetic Acid Extract: Powdered leaves (50 g) from Example 1 are placed in an extraction thimble which is then placed in a Soxhiet extraction apparatus. Methylene chloride (1.5 L) is added to the distillation pot of the Soxhiet apparatus and the solvent is refluxed through the extraction thimble for 24 hours. The defatted leaf residue is removed, dried in air (4 hours), and then dried in vacuo (8 hours). The dried residue and 3% aqueous acetic acid (1.5 L) are added to a 2-L round-bottom flask. The mixture obtained is stirred with a mechanical stirrer for 18 hours. Filtration of the dark green mixture through muslin cloth provides a turbid, dark green solution. The acetic acid in the solution is largely evaporated on a rotary evaporator, and the remaining aqueous solution is freeze-dried to provide a dark green defatted acetic acid extract solid (5.4 g).
Example 5
Preparation of Methanol Extract: Powdered leaves (50 g) from Example 1 are placed in an extraction thimble which is then placed in a Soxhiet extraction apparatus. Methanol (1.5 L) is added to the distillation pot of the Soxhiet apparatus and the solvent is refluxed through the extraction thimble for 12 hours. The methanol solution is evaporated on a rotary evaporator, and the dark gummy residue obtained is dried in vacuo. The dark green solid obtained is crushed to provide a methanol extract powder (3.7 g). Example 6
Preparation of Defatted-Methanol Extract: Powdered leaves (100 g) from Example 1 are placed in an extraction thimble which is then placed in a Soxhiet extraction apparatus. Methylene chloride (1.5 L) is added to the distillation pot of the Soxhiet apparatus and the solvent is refluxed through the extraction thimble for 24 hours. The defatted leaf residue is removed, dried in the air (4 hours), and then dried in vacuo (8 hours). The dried residue is placed in an extraction thimble which is then placed in a Soxhiet extraction apparatus. Methanol (1.5 L) is added to the distillation pot of the Soxhiet apparatus and the solvent is refluxed through the extraction thimble for 24 hours. The methanol solution is evaporated on a rotary evaporator, and the dark residue obtained is dried in vacuo. The dark green solid obtained is crushed to provide a defatted methanol extract powder (14.3 g).
Example 7
Preparation of Acid-Treated, Defatted, Methanol Extract: The defatted methanol extract powder (2 g) of Example 6 is added to an aqueous 0.1N HCl solution (200 mL) and magnetically stirred (5 minutes). The precipitate which forms is removed by filtration and the filtrate is neutralized with an aqueous 0.1N NaOH solution. The solution is freeze-dried to provide a defatted acid-treated methanol extract solid (980 mg).
Example 8
Preparation of Defatted 1-Butanol Extract: The defatted methanol extract powder (3.25 g) of Example 6 is dissolved in distilled water (400 mL) and extracted with 1-butanol (2x100 mL). The 1-butanol portions are evaporated on a rotary evaporator. When most of the 1-butanol is evaporated, water (100 mL) is added to the evaporating flask which is again placed on the rotary evaporator to remove the residual 1-butanol. The aqueous solution which remains is freeze-dried to obtain a defatted 1-butanol extract solid (0.72 g).
Example 9
Preparation of Defatted Acid-Treated 1-Butanol Extract: Powdered leaves (133 g) from Example 1 are placed in an extraction thimble which is then placed in a Soxhiet apparatus. Methylene chloride (1 L) is placed in the distillation pot of the apparatus and the leaf material is continuously extracted for 4 days. The leaf residue is removed from the extraction apparatus and dried in air and then in vacuo. The dried leaf material (115 g) is placed in an extraction thimble which is then placed in a Soxhiet extraction apparatus. Methanol (1.5 L) is added to the distillation pot of the Soxhiet apparatus and the solvent is refluxed through the extraction thimble for 4 days. The methanol solution is evaporated on a rotary evaporator, and the dark residue obtained is dried in vacuo. The dark green solid obtained is crushed to provide defatted methanol extract powder (14.3 g). This extract is then added to 0.1N HCl aqueous solution (600 mL) and magnetically stirred (20 minutes). The solution is placed into vessels which are centrifuged at 5 G. After 10 minutes, the supernatant is removed and the pH is adjusted to 7.8 by the addition of 0.1 N NaOH solution. The aqueous solution is then extracted once with 1-butanol (300 mL). The 1-butanol solution obtained is combined with water (250 ml) and evaporated on a rotary evaporator. When most of the 1-butanol is evaporated, water (100 mL) is added to the evaporating flask which is again placed on the rotary evaporator to remove the residual 1-butanol. The aqueous solution obtained is freeze-dried to provide a defatted acid-treated 1-butanol extract solid (3.37 g).
Example 10
Preparation of Defatted n-Prooanol :Water 1-Butanol Extract: Powdered leaves (50 g) from Example 1 are placed in a 3-speed blender with a speed of 18,000 rpm and blended with 5 x 300 mL n-propanol:distilled water (7:3), 20 seconds at a stretch, five times with every 300 mL n-propanol :distilled water (7:3) added. The mixture is filtered through a G-1 sintered funnel. Filtration of this mixture provides a dark green solution. The n-propanol is largely evaporated on a rotary evaporator and the remaining aqueous solution is extracted with 1 x 200 mL and further 2 x 100 mL hexane for defatting. The aqueous fraction is further extracted with 4 x 100 mL water-saturated 1-butanol. The 1-butanol is evaporated on a rotary evaporator and the dark, gummy residue is dried in vacuo. The dark green solid obtained is crushed to provide a defatted 1-butanol extract (10 g).
Another aspect of the subject invention involves compositions comprising an extract of the subject invention, such as described hereinabove, and a pharmaceutically-acceptable carrier. Preferred compositions are those in dosage forms intended for oral administration. Fluid dosage forms for oral administration include solutions, suspensions, emulsions, and the like. Solid dosage forms for oral administration include tablets, capsules, powders, lozenges, and the like.
The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid filler diluent or encapsulating substance which is suitable for administration to a human or lower animal. The term "compatible" as used herein means that the components of the pharmaceutical carrier are capable of being commingled with the extracts of the subject invention, in a manner such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the composition under ordinary use situations. Pharmaceutically-acceptable carriers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the human or lower animal being treated.
Some examples of substances which can serve as pharmaceutically-acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch, cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate; powdered tragacanth; malts; gelatin; talc; steric acid; magnesium stearate; calcium sulfate; vegetable oil such peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; purified water; emulsifiers, such as the Tweens®; as well as other non-toxic compatible substances used in the pharmaceutical formulation. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, excipients, tableting agents, stabilizers, anti-oxidants, and preservatives, can also be present.
The following are Examples of compositions of the subject invention. They are not intended to be limiting with regard to useful compositions that can be prepared from the extracts of the subject invention.
Example 11
Capsules: The spray-dried powder lemon juice extract of Example 2 is used to prepare capsules by blending 2 parts of the extract with 1 part sucrose and granulating by adding ethanol and blending. The wet granules are dried and passed through a 22-mesh screen; fines are removed with a 30-mesh screen. Hard gelatin capsule shells are filled with 550 mg of granules in each capsule using conventional means.
Example 12
Coated Granules: The dried, powdered acetic acid extract of Example 4 is granulated by blending 6 parts of the powdered extract with 13 parts sucrose and 1 part sodium chloride. These materials are passed through a 40-mesh screen and ethanol is added as the granulating agent. The granules are passed through a 22-mesh screen and dried. Fines are removed with a 30-mesh screen. The granules are transferred to a coating pan and coated initially with 18 parts of a 5% hydroxypropylmethyl cellulose solution (the solvent being a 2:1 mixture of dichloromethane: ethanol) with intermittent addition of 0.14 part of peppermint oil flavor. The granules are then coated with 14 parts of a 2.5% hydroxypropylmethyl cellulose solution followed by drying. The granules are passed through a 16-mesh screen and fines are removed with a 30-mesh screen. The retained granules are packed into sachets.
Example 13
Tablets: The dried, powdered 1-butanol extract of Example 9 is granulated by blending 6 parts with 13 parts sucrose and 1 part sodium chloride, and using ethanol as the granulating liquid. The granules are passed through a 16-mesh screen and dried; fines are removed with a 44-mesh screen. 100 Parts granules are blended with 2 parts talc and 1 part magnesium stearate. This mixture is compressed into 1-gram tablets by conventional means.
Another aspect of the subject invention includes methods for treating or preventing gastrointestinal disorders in humans or lower animals by administering, to a human or lower animal in need of such treatment or prevention, a safe and effective amount of an extract or a composition of the subject invention. This safe and effective amount can be given in a single dose or multiple doses repeatedly over the course of the treatment. Preferred methods of administering the compositions of the subject invention include peroral, intraperitoneal, or directly (e.g., by tube) to the afflicted part of the gastrointestinal tract, especially peroral.
The phrase "safe and effective amount", as used herein, means an amount of the composition of the subject invention high enough to significantly modify the condition to be treated in a positive way, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgement. The safe and effective amount of a composition will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of treatment, the nature of concurrent therapy, the specific composition employed, the particular pharmaceutically-acceptable carrier utilized, and like factors within the knowledge and expertise of the attending physician.
The methods of the subject invention include treatment of humans and lower animals, especially humans, currently suffering from one or more upper or lower gastrointestinal disorders, particularly those specified hereinbefore, in order to reduce the severity of the disorder. The methods of the subject invention also include the prevention of upper or lower gastrointestinal disorders in humans and lower animals, especially humans, having a propensity for such disorders, particularly those specified hereinbefore, by prophylactic treatment in order to prevent occurrence of the disorder. The methods of the subject invention include administering to a human or lower animal a composition comprising an extract of the subject invention. The quantity of extract (dry basis) administered is preferably from about 1 mg/kg to about 1000 mg/kg of body weight, more preferably from about 5 mg/kg to about 500 mg/kg, more preferably still from about 10 mg/kg to about 200 mg/kg. These quantities of extract are preferably administered from about 1 to about 4 times daily, more preferably 2 or 3, or especially about 4 times daily. The extract is preferably administered from about 0 to about 2 hours before meals, more preferably from about 1/2 hour to about 1 hour before meals.
The extracts of the subject invention have a rapid onset of action, and are particularly suitable for treatment of occasional gastrointestinal disorders, such as gastritis, non-ulcer dyspepsia and gastroesophageal reflux disease, as needed. Such disorders are preferably treated using a composition, such that the extract of the subject invention is dosed at a level of from about 1 mg/kg to about 1000 mg/kg, more preferably from about 5 mg/kg to about 500 mg/kg, more preferably still from about 10 mg/kg to about 200 mg/kg, as needed at the onset or during symptomatic episodes of such disorders. If the symptoms persist, additional doses are preferably administered at intervals of from about 1 to about 6 hours, more preferably at intervals of about 2 or 3 or 4 hours.
For prophylactic protection of gastrointestinal disorders, especially NSAID-induced damage, it is preferred that the compositions of the subject invention be administered from 0 to about 6 hours, more preferably from about 1/4 hour to about 3 hours, more preferably still from about 1/2 hour to about 1 hour, prior to administration of the NSAID. For such prophylactic protection, preferred doses of extracts of the subject invention are from about 1 mg/kg to about 1000 mg/kg, more preferably from about 5 mg/kg to about 500 mg/kg, more preferably still from about 10 mg/kg to about 200 mg/kg.
The following are examples of preventing or treating gastrointestinal disorders according to the subject invention. They are not intended to be limiting with regard to methods included within the scope of the invention.
Example 14
A person afflicted with colitis ingests 1 capsule of Example 11 every 8 hours for 7 days to obtain relief from the symptoms of the disease.
Example 15
A person afflicted with gastritis ingests 1 gram of the granulus of Example 12 to obtain rapid relief from the gastritis symptoms.
Example 16
A person determined to be at high risk of developing a gastric ulcer ingests 1 of the tablets of Example 13 daily for 6 months to prevent the occurrence of an ulcer.
While particular embodiments of the subject invention have been described, it will be obvious to those skilled in the art that various changes and modifications to the compositions and methods disclosed herein can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.
WHAT IS CLAIMED IS:

Claims

1. A method for treating or preventing gastrointestinal disorders in humans or lower animals by administering, to a human or lower animal in need of such treatment or prevention, a safe and effective amount of an extract of the tissues of a plant selected from the genera Wedelia, Eclipta and Aspilia.
2. The method of Claim 1 wherein the plant is selected from the following group of species: A. floribunda, A. parvifloia, E. alba, E. erecta, E. prostrata, W. asperrima, W. biflora, W. buphthalmiflora, W. calendulacea, W. calycina, W. chinesis, W. forsteriana, W. glauca, W. grandiflora, W. helian- thoides, W. hispida, W. hookeriana, W. keatingii, W. paludosa, W. parviceps, W. pinetorum, W. scaberrima and W. trilobata; the plant tissue from which the extract is taken comprises the leaves of the plant; the gastrointestinal disorder is selected from the group consisting of gastritis, non-ulcer dyspepsia, gastroesophageal reflux disease, esophagitis, gastric ulcers, duodenal ulcers, gastric cancer, Zollinger-Ellison syndrome, ethanol- induced damage, non-steroidal anti-inflammatory drug (NSAID)- induced damage, ileitis, Crohn's disease, colitis, ulcerative colitis, and inflammatory bowel disease; and the quantity of extract administered is from about 1 mg/kg to about 1000 mg/kg of body weight from about 1 to about 4 times a day.
3. The method of Claim 2 wherein the plant species is E. alba; and the quantity of extract administered is from about 5 mg/kg to about 500 mg/kg.
4. The method of Claim 2 wherein the plant species is W. calendulacea; and the quantity of extract administered is from about 5 mg/kg to about 500 mg/kg.
5. The method of Claim 3 wherein the extract is selected from the group of weak acid, alcohol, and alcohol/1-butanol extracts.
6. The method of Claim 4 wherein the extract is selected from the group of weak acid, alcohol, and alcohol/1-butanol extracts.
7. The method of Claim 6 wherein the extract is a methanol/1-butanol extract.
8. The method of any of Claims 2-4 wherein the gastrointestinal disorder is an upper gastrointestinal disorder.
9. The method of any of Claims 5-7 wherein the method is for treatment of a gastrointestinal disordered selected from the group consisting of gastritis, non-ulcer dyspepsia and NSAID- induced damage.
10. The method of any of Claims 5-7 wherein the method is for prophylactic protection frcm gastrointestinal disorders selected from the group consisting of gastric ulcers, ethanol- induced damage and NSAID-induced damage.
11. A lemon juice extract of plant tissues, the tissues comprising the leaves of a plant selected from the group of plant genera consisting of Wedelia, Eclipta and Aspilia.
12. A composition comprising from about 1% to about 95% of the extract of Claim 11, wherein the plant species is W. calendulacea; and from about 5% to about 99% of a pharma- ceutically-acceptable carrier.
13. An alcohol/1-butanol extract of plant tissues, the tissues comprising the leaves of a plant selected from the group of plant genera consisting of Wedelia, Eclipta and Aspilia.
14. A composition comprising from about 1% to about 95% of the extract of Claim 13, wherein the plant species is W. calendulacea; and from about 5% to about 99% of a pharmaceutically-acceptable carrier.
15. The composition of Claim 14 wherein the extract is a methanol/1-butanol extract.
16. A process for preparing a lemon juice extract of plant tissues comprising extracting the plant tissues with lemon juice, wherein the plant tissues comprise leaves of a plant selected from the plant genera consisting of Wedelia, Eclipta and Aspilia.
17. The process of Claim 16 wherein the plant species is W. calendulacea.
18. A process for preparing an alcohol/1-butanol extract of plant tissues, the plant tissues comprising leaves of a plant selected frcm the group of plant genera consisting of Wedelia, Eclipta and Aspilia, comprising the following steps: (a) extracting the plant tissues with a solvent consisting essentially of frcm about 50% to about 100% of a water-miscible alcohol and from 0% to about 50% water, (b) then removing substantially all of the alcohol frcm the resulting extract, (c) then optionally adding water if needed to provide an aqueous solution, and (d) then extracting the aqueous solution with 1-butanol.
19. The process of Claim 18 wherein the plant species is W. calendulacea.
20. The process of Claim 19 wherein the water-miscible alcohol is methanol.
21. Use of an extract of the tissues, preferably the leaves, of a plant selected from the genera Wedelia, Eclipta and Aspilia for manufacture of a medicament for treating or preventing gastrointestinal disorders in humans or lower animals.
22. The use of Claim 21 characterized in that the plant is selected from the species A. floribunda, A. parvifloia, E. alba, E. erecta, E. prostrata, W. asperrima, W. biflora, W. buphthalmiflora, W. calendulacea, W. calycina, W. chinesis, W. forsteriana, W. glauca, W. grandiflora, W. heliantholdes, W. hispida, W. hookeriana, W. keatingii, W. paludosa, W. parviceps, W. pinetorum, W. scaberrima and W. trilobata; preferably from the species E. alba or especially W. calendulacea; and the gastrointestinal disorder is selected from gastritis, non-ulcer dyspepsia, gastroesophageal reflux disease, esophagitis, gastric ulcers, duodenal ulcers, gastric cancer, Zollinger-Ellison syndrome, ethanol-induced damage, non-steroidal anti-inflammatory drug (NSAID)-induced damage, ileitis, Crohn's disease, colitis, ulcerative colitis, and inflammatory bowel disease; preferably from gastritis, non-ulcer dyspepsia, and NSAID-induced damage.
23. The use of Claim 21 or 22 characterized in that the quantity of extract administered is frcm 1 mg/kg to 1000 mg/kg of bod/ weight, preferably from 5 mg/kg to 500 mg/kg, from 1 to 4 times a day.
24. The use of Claim 21, 22, or 23 characterized in that the extract is selected from weak acid, alcohol, and alcohol/ 1-butanol extracts, preferably is a methanol/1-butanol extract.
25. The use of any of Claims 21-24 wherein the use is for prophylactic protection frcm gastrointestinal disorders selected from gastric ulcers, ethanol-induced damage and NSAID-induced damage.
26. A lemon juice extract of plant tissues, the tissues comprising the leaves of a plant selected from the plant genera Wedelia, Eclipta and Aspilia, preferably from the plant species E. alba or especially W. calendulacea.
27. An alcohol/1-butanol extract, preferably a methanol/ 1-butanol extract, of plant tissues, the tissues comprising the leaves of a plant selected from the plant genera Wedelia, Eclipta and Aspilia, preferably from the plant species E. alba or especially W. calendulacea.
28. A composition conprising from 1% to 95% or the extract of Claim 26 or 27, and from 5% to 99% of a pharmaceutically- acceptable carrier.
29. A process for preparing a lemon juice extract of plant tissues comprising extracting the plant tissues with lemon juice, wherein the plant tissues comprise leaves of a plant selected from the plant genera Wedelia, Eclipta and Aspilia, preferably from the plant species E. alba, or especially W. calendulacea.
30. A process for preparing an alcohol/1-butanol extract of plant tissues, the plant tissues conprising leaves of a plant selected from the plant genera Wedelia, Eclipta and Aspilia, preferably from the plant species E. alba or especially W. calendulacea, comprising the following steps: (a) extracting the plant tissues with a solvent consisting essentially of from 50% to 100% of a water-miscible alcohol, preferably methanol, and from 0% to 50% water, (b) then removing substantially all of the alcohol frcm the resulting extract, (c) then optionally adding water if needed to provide an aqueous solution, and (d) then extracting the aqueous solution with 1-butanol.
PCT/US1991/007014 1990-10-12 1991-09-26 Plant extracts as mucosal-protective agents WO1992006699A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59846290A 1990-10-12 1990-10-12
US598,462 1990-10-12

Publications (1)

Publication Number Publication Date
WO1992006699A1 true WO1992006699A1 (en) 1992-04-30

Family

ID=24395634

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1991/006978 WO1992006984A1 (en) 1990-10-12 1991-09-25 Process for preparing n-alkyl polyhydroxy amines and fatty acid amides therefrom in hydroxy solvents
PCT/US1991/007014 WO1992006699A1 (en) 1990-10-12 1991-09-26 Plant extracts as mucosal-protective agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006978 WO1992006984A1 (en) 1990-10-12 1991-09-25 Process for preparing n-alkyl polyhydroxy amines and fatty acid amides therefrom in hydroxy solvents

Country Status (27)

Country Link
US (1) US5334764A (en)
EP (1) EP0558515B1 (en)
JP (1) JPH06501688A (en)
CN (1) CN1040112C (en)
AR (1) AR244238A1 (en)
AT (1) ATE155139T1 (en)
AU (2) AU660628B2 (en)
BR (1) BR9106897A (en)
CA (1) CA2092192C (en)
CZ (1) CZ32093A3 (en)
DE (1) DE69126789T2 (en)
EG (1) EG19521A (en)
ES (1) ES2103830T3 (en)
FI (1) FI931573A (en)
HU (1) HUT63849A (en)
IE (1) IE913422A1 (en)
MA (1) MA22317A1 (en)
MX (1) MX9101371A (en)
MY (1) MY107788A (en)
NO (1) NO931213D0 (en)
NZ (1) NZ240043A (en)
PL (1) PL168355B1 (en)
PT (1) PT99103A (en)
SK (1) SK21793A3 (en)
TR (1) TR25865A (en)
TW (1) TW224136B (en)
WO (2) WO1992006984A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2029150A4 (en) * 2006-02-28 2009-12-16 Dong A Pharm Co Ltd Extract of herbal and the composition containing the same

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4234376A1 (en) * 1992-10-12 1994-04-14 Henkel Kgaa Recyclables and mixtures of substances for wetting, washing and / or cleaning agents in a new formulation
DE69303708T2 (en) * 1992-03-16 1997-02-27 Procter & Gamble LIQUID COMPOSITIONS CONTAINING POLYHYDROXY FATTY ACID
US5188769A (en) * 1992-03-26 1993-02-23 The Procter & Gamble Company Process for reducing the levels of fatty acid contaminants in polyhydroxy fatty acid amide surfactants
DE4229442A1 (en) * 1992-09-03 1994-03-10 Henkel Kgaa Dispersant
EP0592754A1 (en) * 1992-10-13 1994-04-20 The Procter & Gamble Company Fluid compositions containing polyhydroxy fatty acid amides
DE4310032C2 (en) * 1993-03-27 2000-01-05 Suedzucker Ag Stereoisomeric mixture of 1-N-alkylamino-1-deoxy-6-0- [alpha-D-glucopyranosyl] -D-sorbitol and 1-N-alkylamino-1-deoxy-6-0- [alpha-D-glucopyranosyl] -D-mannitol, process for its preparation and its use
DE4323253C1 (en) * 1993-07-12 1995-01-05 Henkel Kgaa Use of fatty acid N-alkyl polyhydroxyalkylamides as rinse aid for machine cleaning hard surfaces
DE4331297A1 (en) * 1993-09-15 1995-03-16 Henkel Kgaa Bar soaps
DE4337032C1 (en) * 1993-10-29 1995-05-24 Henkel Kgaa Use of detergent mixtures for the production of toilet blocks
DE4340015C2 (en) * 1993-11-24 1996-07-04 Henkel Kgaa Process for the production of anhydrous, free-flowing sugar surfactant powder and their use
EP0659870A1 (en) * 1993-11-26 1995-06-28 The Procter & Gamble Company N-alkyl polyhydroxy fatty acid amide compositions and their method of synthesis
US5750748A (en) * 1993-11-26 1998-05-12 The Procter & Gamble Company N-alkyl polyhydroxy fatty acid amide compositions and their method of synthesis
DE4400632C1 (en) * 1994-01-12 1995-03-23 Henkel Kgaa Surfactant mixtures and compositions containing these
DE4404633A1 (en) * 1994-02-14 1995-08-17 Henkel Kgaa Process for the production of practically anhydrous sugar surfactants
US5691295A (en) * 1995-01-17 1997-11-25 Cognis Gesellschaft Fuer Biotechnologie Mbh Detergent compositions
DE4409321A1 (en) * 1994-03-18 1995-09-21 Henkel Kgaa Low m.pt fatty acid isethionate-based detergent mixt.
DE4413686C2 (en) * 1994-04-20 1996-10-24 Henkel Kgaa Cationic sugar surfactants, process for their preparation and their use
DE4414815C2 (en) * 1994-04-28 1997-03-06 Henkel Kgaa Use of selected anionic surfactants as crystallization inhibitors for sugar surfactant pastes
EP0693549A1 (en) 1994-07-19 1996-01-24 The Procter & Gamble Company Solid bleach activator compositions
DE4443643A1 (en) * 1994-12-08 1996-06-13 Henkel Kgaa Prepn. of anionic glucamide detergents without strong oxidn. of sugar components
US5627273A (en) * 1995-01-31 1997-05-06 National Starch And Chemical Investment Holding Corporation Method for preparing hydrophobically-terminated polysaccharide polymers and detergent compositions comprising the polysaccharide polymers
DE19511572C2 (en) * 1995-03-29 1998-02-26 Henkel Kgaa Low-viscosity opacifier concentrates
DE19511670A1 (en) * 1995-03-30 1996-10-02 Henkel Kgaa Process for the preparation of aqueous surfactant concentrates
GB9508023D0 (en) * 1995-04-20 1995-06-07 Scotia Holdings Plc Fatty acid derivatives
US5646318A (en) * 1995-04-26 1997-07-08 Akzo Nobel Nv Process for the preparation of hydroxyalkylamides
US5563252A (en) * 1995-06-05 1996-10-08 National Starch And Chemical Investment Holding Corporation Polymerizable saccharide monomers which contain a single, polymerizable, α-methyl styryl moiety
US6040406A (en) * 1995-06-05 2000-03-21 National Starch And Chemical Investment Holding Corporation Detectable water-treatment polymers and methods for monitoring the concentration thereof
US5618876A (en) * 1995-06-05 1997-04-08 National Starch And Chemical Investment Holding Corporation Latex binders and coatings containing polymers derived from polymerizable saccharide monomers
US5654198A (en) * 1995-06-05 1997-08-05 National Starch And Chemical Investment Holding Corporation Detectable water-treatment polymers and methods for monitoring the concentration thereof
US5719244A (en) * 1995-06-05 1998-02-17 National Starch And Chemical Investment Holding Corporation Latex binders and coatings containing polymers derived from polymerizable saccharide monomers
US5777165A (en) * 1995-06-07 1998-07-07 The Procter & Gamble Company Process for preparing amides of N-alkyl polyhydroxyalkyl amines
US5723673A (en) * 1995-06-07 1998-03-03 The Procter & Gamble Company Process for preparing amides of N-alkyl polyhydroxyalkyls
DE19524244C1 (en) 1995-07-04 1997-02-20 Henkel Kgaa Nonionic surfactant concentrates
DE19524464C2 (en) * 1995-07-10 2000-08-24 Cognis Deutschland Gmbh Process for the production of sugar surfactant granules
DE19533539A1 (en) 1995-09-11 1997-03-13 Henkel Kgaa O / W emulsifiers
DE19533790A1 (en) * 1995-09-13 1997-03-20 Henkel Kgaa Process for the preparation of an amorphous alkali silicate with impregnation
DE19543633C2 (en) 1995-11-23 2000-08-17 Cognis Deutschland Gmbh Cosmetic and / or pharmaceutical preparations
DE19544710C2 (en) 1995-11-30 1998-11-26 Henkel Kgaa Thickener
DE19548068C1 (en) 1995-12-21 1997-06-19 Henkel Kgaa Process for the production of light colored, low viscosity surfactant concentrates
US5932535A (en) * 1995-12-21 1999-08-03 Henkel Kommanditgesellschaft Auf Aktien Process for the production of light-colored, low-viscosity surfactant concentrates
WO1997026095A1 (en) * 1996-01-18 1997-07-24 Henkel Corporation Process for soil remediation
US5786320A (en) * 1996-02-01 1998-07-28 Henkel Corporation Process for preparing solid cast detergent products
DE19606620C2 (en) * 1996-02-22 1999-01-07 Henkel Kgaa Reductive bleaching process
US5770549A (en) * 1996-03-18 1998-06-23 Henkel Corporation Surfactant blend for non-solvent hard surface cleaning
US6033652A (en) * 1996-05-15 2000-03-07 Henkel Kommanditgesellschaft Auf Aktien Hair-treatment formulations
DE19623383C2 (en) 1996-06-12 1999-07-01 Henkel Kgaa Use of fatty substances as a silicone substitute for the production of cosmetic and / or pharmaceutical preparations
DE19641274C1 (en) 1996-10-07 1998-02-12 Henkel Kgaa Oil in water microemulsion sun protection cosmetic products
DE19641275C1 (en) 1996-10-07 1998-03-12 Henkel Kgaa Process for the preparation of water and dust-free anionic surfactant granules
DE19646869C1 (en) 1996-11-13 1997-12-04 Henkel Kgaa Cosmetic formulation containing cationic polymer, especially pearly shampoo, giving stable aqueous formulation
DE19646867C1 (en) 1996-11-13 1997-12-04 Henkel Kgaa Cosmetic formulation containing silicone compound, especially pearly shampoo, giving stable aqueous formulation
DE19710153C1 (en) 1997-03-12 1998-02-12 Henkel Kgaa Neutral sugar surfactant granulation from e.g. alkyl oligo:glycoside
DE19725508A1 (en) 1997-06-17 1998-12-24 Clariant Gmbh Detergents and cleaning agents
EP1007619A1 (en) 1997-08-25 2000-06-14 Cognis Deutschland GmbH Hard soap containing fatty acid polyglycol ester sulphates
US5883070A (en) * 1997-10-08 1999-03-16 Henkel Corporation Process for preparing zeolite slurries using a nonionic sugar surfactant and electrolyte
US6069121A (en) * 1998-05-15 2000-05-30 Henkel Corporation Superfatted personal cleansing bar containing alkyl polyglycoside
DE19830267A1 (en) 1998-07-07 2000-01-13 Henkel Kgaa Hand dishwashing liquid
US6225389B1 (en) 1998-08-20 2001-05-01 Henkel Corp. Screen coating composition and method for applying same
DE19843384A1 (en) 1998-09-22 2000-03-23 Cognis Deutschland Gmbh Reducing viscosity of aqueous surfactant systems using alkoxylated carboxylic acid esters preferably obtained in presence of calcined hydrotalcite
US6584988B1 (en) 1998-10-30 2003-07-01 Cognis Corp. Process for removing contaminants from water
DE19851453A1 (en) 1998-11-09 2000-05-11 Cognis Deutschland Gmbh Rinse aid for automatic dishwashing
DE19856727A1 (en) 1998-12-09 2000-06-15 Cognis Deutschland Gmbh All-purpose cleaner
DE19909907A1 (en) * 1999-03-06 2000-09-07 Clariant Gmbh Process for the preparation of N-alkyl polyhydroxyalkylamines from monoalkylamine and reducing sugar
US6680347B1 (en) 1999-10-05 2004-01-20 Cognis Corporation Self-dispersible epoxide/surfactant coating compositions
DE10005556A1 (en) 2000-02-09 2001-08-23 Cognis Deutschland Gmbh Highly viscous microemulsions, used for producing cosmetic gel and stick formulations, especially antiperspirants and deodorants, contain sugar surfactants, oil bodies and aluminum-zirconium salts
DE10009996B4 (en) 2000-03-02 2005-10-13 Cognis Ip Management Gmbh Solid granules with monodisperse particle size distribution, a process for their preparation and their use
DE10018812A1 (en) 2000-04-15 2001-10-25 Cognis Deutschland Gmbh Nonionic surfactant granulate, used in surfactant, cosmetic or pharmaceutical formulation or laundry or other detergent, is obtained by granulating and simultaneously drying aqueous surfactant paste in presence of organic polymeric carrier
DE10020887A1 (en) 2000-04-28 2001-10-31 Henkel Kgaa Improving the wash-fastness and dye intensity of dyed fibers (especially keratin) using a combination of sugar surfactants with fatty acid partial glycerides and optionally also polymers
DE10113446A1 (en) 2001-03-19 2002-09-26 Schwarzkopf Gmbh Hans Pharmaceutical or cosmetic hair treatment agents, especially for promoting hair growth, contain a betaine, especially carnitine, histidine, taurine, choline or betaine or their derivatives
EP1572851B1 (en) 2002-12-20 2007-03-21 Henkel Kommanditgesellschaft auf Aktien Bleach-containing washing or cleaning agents
US7250392B1 (en) 2003-03-07 2007-07-31 Cognis Corporation Surfactant blend for cleansing wipes
DE10338883A1 (en) 2003-08-23 2005-03-24 Hans Schwarzkopf & Henkel Gmbh & Co. Kg Process for smoothing keratin-containing fibers
US20070267035A1 (en) 2004-09-07 2007-11-22 Henkel Kommanditgesellschaft Auf Aktien Composition and Method for the Smoothing of Fibres Containing Keratin
DE102004045274A1 (en) 2004-09-16 2006-03-23 Henkel Kgaa Active substance mixture for the treatment of keratinic fibers
US20060100127A1 (en) * 2004-11-11 2006-05-11 Meier Ingrid K N,N-dialkylpolyhydroxyalkylamines
DE102005025933B3 (en) * 2005-06-06 2006-07-13 Centrotherm Photovoltaics Gmbh + Co. Kg Doping mixture for preparing and doping semiconductor surfaces, comprises a p- or n-dopant, for doping the semiconductor surfaces, water and mixture of two or more surfactants, where one of the surfactant is a non-ionic surfactant
CN100383154C (en) * 2005-12-13 2008-04-23 北京服装学院 Gemini boric acid ester glucose acylamine compound, and its preparing method and use
DE102005062268A1 (en) 2005-12-24 2007-08-02 Henkel Kgaa Powdered styling agents and their dispensing systems
DE102006031151A1 (en) 2006-07-04 2008-01-10 Merck Patent Gmbh fluorosurfactants
DE102006031149A1 (en) 2006-07-04 2008-01-10 Merck Patent Gmbh fluorosurfactants
CN100465157C (en) * 2006-11-10 2009-03-04 中国日用化学工业研究院 Preparation process for synthesizing AGA using loop reactor
DE102006061555A1 (en) 2006-12-27 2008-07-03 Henkel Kgaa Cosmetic preparation for the cleaning and treatment of skin and hair, contains, as active ingredients, natural silk or its derivatives and a Sub-Group 1 or 8 metal or metal salt, e.g. gold or silver
DE102007001008A1 (en) 2007-01-02 2008-07-03 Henkel Kgaa Cosmetic composition useful for protecting hair from oxidative damage comprises an ayurvedic plant extract
DE102007001027A1 (en) 2007-01-02 2008-07-03 Henkel Kgaa Cosmetic preparation, e.g. for care and conditioning of hair after permanent waving or dyeing, contains a combination of palmitic, palmitoleic, stearic, oleic and linoleic acids
DE102007001019A1 (en) 2007-01-02 2008-07-03 Henkel Kgaa Cosmetic compositions useful for care and conditioning of keratinic fibers, especially hair, comprise a mineral powder and a cationic, amphoteric or zwitterionic polymer
DE102007001028A1 (en) 2007-01-02 2008-07-03 Henkel Kgaa Cosmetic preparation, e.g. for care and conditioning of hair after permanent waving or dyeing, contains a synergistic combination of argan oil and shea butter
DE102007023827A1 (en) 2007-05-21 2008-11-27 Henkel Ag & Co. Kgaa Use of polycarbonate, polyurethane and/or polyurea-polyorganosiloxane compounds or their acid addition compounds and/or salts to improve the cleaning efficiency of laundry detergents during washing textiles
DE102007023870A1 (en) 2007-05-21 2008-11-27 Henkel Ag & Co. Kgaa Use of an active agent containing (1,3)dioxolan-2-one compound or (1,3)diazepan-2-one compound, and a polymer, for strengthening the primarily washing power of the detergent in the washing of textile oil- and/or fat-containing dirt
DE102007056935A1 (en) 2007-11-23 2009-05-28 Henkel Ag & Co. Kgaa Two-component aerosol hair color
DE102009009004A1 (en) 2008-02-18 2009-09-17 Seaquist Perfect Dispensing Gmbh Dispensing device, preferably pump preferably with a sprayable and/or non-sprayable cosmetic liquid, where the cosmetic liquid comprises single phase solution, mixture of non-miscible liquid phases, and oil-in-water-/water-in-oil-emulsion
DE102008002707A1 (en) 2008-06-27 2009-12-31 Evonik Goldschmidt Gmbh Hair treatment compositions and hair aftertreatment agents for protection against damage caused by chemical treatment and for repairing damaged hair already containing etherguanidines as active substances
DE102008064218A1 (en) 2008-12-22 2010-07-01 Henkel Ag & Co. Kgaa Process for dyeing and shaping keratin-containing fibers
DE102009031432A1 (en) 2009-07-01 2011-01-05 Henkel Ag & Co. Kgaa Compact hair spray
CN101863793A (en) * 2010-06-25 2010-10-20 凤台精兴生物科技有限公司 Synthesizing method of N-methyl glucamine
DE102015222976A1 (en) 2015-11-20 2017-05-24 Henkel Ag & Co. Kgaa Hair care compositions containing casein hydrolyzate for improving the hair structure
DE102015223196A1 (en) 2015-11-24 2017-05-24 Henkel Ag & Co. Kgaa Agents and methods for cleaning and / or caring for damaged keratinic fibers
FR3060005A1 (en) 2016-12-12 2018-06-15 Ecole Nationale Superieure De Chimie PROCESS FOR THE PREPARATION OF SURFACTANT COMPOSITIONS COMPRISING ALKYL L-IDURONAMIDES, D-GLUCURONAMIDES AND L-RHAMNOSIDES FROM ULVANES
CN107188816B (en) * 2017-06-14 2023-06-06 上海欧睿生物科技有限公司 Improved synthesis method of fatty acid monoethanolamide
EP3533435B1 (en) 2018-02-28 2022-07-13 Kao Corporation Cleansing and conditioning composition for keratin fibers, method, use, and kit-of-parts thereof
US20210038496A1 (en) 2018-03-21 2021-02-11 Kao Germany Gmbh Process for conditioning of keratin fibers
DE202018006763U1 (en) 2018-11-29 2022-08-18 Kao Germany Gmbh Composition for straightening keratin fibers
EP3659577A1 (en) 2018-11-29 2020-06-03 Kao Germany GmbH Keratin fiber straightening composition, process, and kit-of-parts
US20230035776A1 (en) 2018-12-03 2023-02-02 Carbonet Nanotechonologies Inc. Nanonets for removal of contaminants from aqueous solutions, kits therefor and methods of their use
EP3662887A1 (en) 2018-12-06 2020-06-10 Kao Germany GmbH Process for reshaping keratin fibers
EP3662886A1 (en) 2018-12-06 2020-06-10 Kao Germany GmbH Process for reshaping keratin fibers
EP3662888A1 (en) 2018-12-06 2020-06-10 Kao Germany GmbH Process for reshaping keratin fibers
EP3662885A1 (en) 2018-12-06 2020-06-10 Kao Germany GmbH Process for reshaping keratin fibers
EP3977977A1 (en) 2020-09-30 2022-04-06 Kao Corporation Cleansing composition comprising internal olefin sulfonate surfactant
US20220192969A1 (en) 2020-12-17 2022-06-23 Kao Corporation Solid composition for keratin fibers
EP4194533A1 (en) 2021-12-08 2023-06-14 The Procter & Gamble Company Liquid hand dishwashing detergent composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525363A1 (en) * 1985-07-16 1987-01-22 Puetter Medice Chem Pharm Process for the preparation of extracts of Eclipta alba standardized for wedelolactone and/or desmethylwedelolactone and use of the extracts for the preparation of a liver therapeutic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2016962A (en) * 1932-09-27 1935-10-08 Du Pont Process for producing glucamines and related products
US1985424A (en) * 1933-03-23 1934-12-25 Ici Ltd Alkylene-oxide derivatives of polyhydroxyalkyl-alkylamides
GB519381A (en) * 1937-09-21 1940-03-26 Du Pont Manufacture of maltosamines
US2703798A (en) * 1950-05-25 1955-03-08 Commercial Solvents Corp Detergents from nu-monoalkyl-glucamines
US3257436A (en) * 1962-11-06 1966-06-21 Witco Chemical Corp Preparation of amides of hydroxy non-tertiary amines
DK131638A (en) * 1969-06-07
US4711730A (en) * 1986-04-15 1987-12-08 The Procter & Gamble Company Capped 1,2-propylene terephthalate-polyoxyethylene terephthalate polyesters useful as soil release agents
GB8627181D0 (en) * 1986-11-13 1986-12-10 Procter & Gamble Softening detergent compositions
DE3711776A1 (en) * 1987-04-08 1988-10-27 Huels Chemische Werke Ag USE OF N-POLYHYDROXYALKYL Fatty Acid Amides As Thickeners For Liquid Aqueous Surfactant Systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525363A1 (en) * 1985-07-16 1987-01-22 Puetter Medice Chem Pharm Process for the preparation of extracts of Eclipta alba standardized for wedelolactone and/or desmethylwedelolactone and use of the extracts for the preparation of a liver therapeutic

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARZNEIMITTELFORSCHUNG, Vol. 38, No. 5, May 1988, Aulendorf, DE., WONG S.M. et al., "Wedelolactone and Coumestan Derivatives as New Antihepatotoxic and Antiphlogistic Principles", pages 661-665. *
JOURNAL OF ETHNOPHARMACOLOGY, Vol. 25, No. 1, February 1990, Ireland, SHARMA et al., "Hepatoprotective Effects of Wedelia Calendulacea", pages 93-102. *
TOXICON, Vol. 27, No. 9, 1989, Oxford, UK., MORS W.B. et al., "Neutralization of Lethal and Myotoxic Activities of South American Rattlesnake Venom by Extracts and Constituents of the Plant Eclipta Prostrata (Asteraceae)", pages 1003-1009. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2029150A4 (en) * 2006-02-28 2009-12-16 Dong A Pharm Co Ltd Extract of herbal and the composition containing the same
EP2206508A3 (en) * 2006-02-28 2010-10-13 Dong-A Pharm. Co., Ltd. Extract of herbal and the composition containing the same

Also Published As

Publication number Publication date
AU660628B2 (en) 1995-07-06
AU8768291A (en) 1992-05-20
ES2103830T3 (en) 1997-10-01
MX9101371A (en) 1992-06-05
MA22317A1 (en) 1992-07-01
TR25865A (en) 1993-09-01
HUT63849A (en) 1993-10-28
ATE155139T1 (en) 1997-07-15
EP0558515B1 (en) 1997-07-09
CN1040112C (en) 1998-10-07
AR244238A1 (en) 1993-10-29
HU9300764D0 (en) 1993-07-28
US5334764A (en) 1994-08-02
PT99103A (en) 1992-08-31
NO931213L (en) 1993-03-31
BR9106897A (en) 1993-08-24
SK21793A3 (en) 1993-07-07
NZ240043A (en) 1994-06-27
TW224136B (en) 1994-05-21
CZ32093A3 (en) 1993-12-15
EG19521A (en) 1995-09-30
NO931213D0 (en) 1993-03-31
MY107788A (en) 1996-06-15
JPH06501688A (en) 1994-02-24
IE913422A1 (en) 1992-04-22
CN1061958A (en) 1992-06-17
FI931573A0 (en) 1993-04-07
CA2092192A1 (en) 1992-04-13
DE69126789T2 (en) 1998-02-12
AU8907291A (en) 1992-05-20
CA2092192C (en) 1998-08-18
EP0558515A1 (en) 1993-09-08
PL168355B1 (en) 1996-02-29
FI931573A (en) 1993-04-07
DE69126789D1 (en) 1997-08-14
WO1992006984A1 (en) 1992-04-30

Similar Documents

Publication Publication Date Title
WO1992006699A1 (en) Plant extracts as mucosal-protective agents
US5130133A (en) Plant extracts as mucosal-protective agents
JP2022009308A (en) Composition for ameliorating climacteric symptoms or osteoporosis
RU2431494C1 (en) Antiparasitic tea
JP7385325B2 (en) Composition for improving locomotive syndrome
KR100601390B1 (en) Anti-Obesity ingredients from medicinal plants and their composition
JP4516958B2 (en) Anti-diabetic composition
CN110167570B (en) Composition for preventing or treating gastritis or peptic ulcer
KR100878436B1 (en) Pharmaceutical composition comprising extract of lonicera japonica for prevention and treatment of digestive ulcer
JP6369931B2 (en) Anti-obesity agent
KR102242195B1 (en) Composition for improving, preventing or treating non-alcoholic liver disease and preparation method thereof
WO2008091064A1 (en) Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases
KR101934810B1 (en) Preparation for improving blood circulation comprising oriental medicinal extracts
JP2000072685A (en) Food and medicament compositions for inhibiting ulcer of digestive organ
KR100446061B1 (en) Pharmaceutical composition and health improving food for prevention or treatment of hangover comprising microspherical crude drug powder having organic solvent adsorptive activity
Rao et al. Hypolipidemic effect of dichloromethane as well as methanolic fruit and leaf extract of Ethiopian alligator pear (persea americana mill.) on tyloxapol-induced hyperlipidemic experimental rat
RU2773856C1 (en) Drug with a hypoglycemic effect and a method for obtaining it
RU2773856C9 (en) Drug with a hypoglycemic effect and a method for obtaining it
KR20140083493A (en) Composition for anti-obesity comprising extract of Sargassum fulvellum or Sargassum horneri as an effective component
RU2259835C2 (en) Method for preparing anti-inflammatory, wound-healing, capillary-strengthening and immunomodulating agent
US20040033275A1 (en) Method for the production of phyllanthus extracts
EP3545947B1 (en) Composition for the reduction of plasma levels of uric acid
Baby et al. An Ethanopharmacological review on Morinda citrifolia
KR20120113459A (en) Compositions for skin whitening comprising essential oils from artemisia, lemon and fennel
KR101072725B1 (en) Composition containing as available ingredient the extracts of Bupleurum falcatum L.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA